Open AccessImmunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade
Author(s) -
Jun Zhou,
Jingjing Li,
Indira Guleria,
Tianqi Chen,
Anita GiobbieHurder,
Jonathan Stevens,
Meghna Gupta,
Xinqi Wu,
Ryan Brennick,
Michael P. Manos,
F. Stephen Hodi
Publication year - 2019
Publication title -
cancer immunology, immunotherapy/cancer immunology and immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.389
H-Index - 115
eISSN - 1432-0851
pISSN - 0340-7004
DOI - 10.1007/s00262-019-02370-4
Subject(s) - xiap , inhibitor of apoptosis , melanoma , ipilimumab , cancer research , survivin , apoptosis , peripheral blood mononuclear cell , immunology , immune system , immunotherapy , immune checkpoint , blockade , biology , medicine , programmed cell death , caspase , receptor , in vitro , biochemistry
Expression of inhibitors of apoptosis protein (IAP) family members is associated with poor prognosis in cancer patients. Immunity to ML-IAP (livin) and survivin has been well studied in patients with a variety of tumors. XIAP, the most potent inhibitor of apoptosis, is widely expressed in melanoma. To better define its potential role as an immunogenic target, cellular and humoral responses to XIAP were investigated in patients with advanced melanoma. An overlapping peptide library covering the full length of the XIAP protein was used to screen T cell responses of peripheral blood mononuclear cells (PBMC) from stage-IV melanoma patients treated with or without anti-CTLA4 (ipilimumab). The screen identified an array of peptides that predominantly induced CD4 + T cell responses. XIAP epitope-specific CD4 + T cells revealed proliferative responses to melanoma cells that express XIAP. Humoral responses to XIAP were also explored. Cellular and humoral responses to XIAP were associated with beneficial clinical outcomes after ipilimumab-based treatment, supporting XIAP as a potential therapeutic target.